Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic, slow-release protein material reduces the severity of SARS-CoV-2 infection

  • Parladé, Eloi|||0000-0001-5750-550X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Márquez-Matínez, Merce
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Roca, Núria
  • Pérez, Mónica
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Villaverde, Antonio|||0000-0002-2615-4521
Slow-antigen release vaccination systems aim to replicate the prolonged antigen exposure occurring during natural viral infections, which usually last for days or weeks. We have developed a Zn-assisted, self-organizing protein material at the microscale, inspired by the granular depots for protein hormones, that slowly disassembles into functional building block polypeptides under physiological conditions. This endocrine-like platform acts as a dynamic protein depot for prolonged protein release. Having been validated in oncology, regenerative medicine, and in antimicrobial peptide delivery, it also shows promise for immune stimulation. Here, we evaluate, for the first time, whether such artificial secretory granules incorporating the SARS-CoV-2 Spike Receptor Binding Domain (RBD) can elicit a protective immune response against viral challenge in golden Syrian hamsters. The antigen, formulated as secretory granules, was administered in varying doses via intranasal or subcutaneous routes. While the formulations did not prevent infection, they enhanced viral clearance and mitigated body weight loss, particularly with subcutaneous administration. These effects, through the subcutaneous route, were achieved even in the absence of an adjuvant. Additionally, the granules triggered both antigen-specific humoral immunity and antigen-independent immunomodulatory effects, potentially linked to their amyloid-like structure. These findings demonstrate the dual mechanism of this platform, activating both adaptive and innate immune pathways, and its potential as a versatile, adjuvant-free system for enhancing immune responses against infectious diseases.
Dipòsit Digital de Documents de la UAB
Research data Set de datos (Dataset)

Dataset for the following MS with provisional title, Ion-dependent slow protein release from in vivo disintegrating micro-granules

  • Álamo, Patricia|||0000-0003-0510-5701
  • Parladé, Eloi|||0000-0001-5750-550X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
Set DATASET that accompains the manuscript by Alamo and co-workers provisionally entitled Ion-dependent slow protein release from in vivo disintegrating micro-granules.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ion-dependent slow protein release from in vivo disintegrating micro-granules

  • Álamo, Patricia|||0000-0003-0510-5701
  • Parladé, Eloi|||0000-0001-5750-550X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
Through the controlled addition of divalent cations, polyhistidine-tagged proteins can be clustered in form of chemically pure and mechanically stable micron-scale particles. Under physiological conditions, these materials act as self-disintegrating protein depots for the progressive release of the forming polypeptide, with potential applications in protein drug delivery, diagnosis, or theragnosis. Here we have explored the in vivo disintegration pattern of a set of such depots, upon subcutaneous administration in mice. These microparticles were fabricated with cationic forms of either Zn, Ca, Mg, or Mn, which abound in the mammalian body. By using a CXCR4-targeted fluorescent protein as a reporter building block we categorized those cations regarding their ability to persist in the administration site and to sustain a slow release of functional protein. Ca and specially Zn have been observed as particularly good promoters of time-prolonged protein leakage. The released polypeptides result is available for selective molecular interactions, such as specific fluorescent labeling of tumor tissues, in which the protein reaches nearly steady levels.
Dipòsit Digital de Documents de la UAB
Research data Set de datos (Dataset)

Raw data from a MS with the tentative title, Cell penetration of receptor-targeted protein-only nanoparticles assisted by the translocation domain of the diphtheria toxin

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Parladé, Eloi|||0000-0001-5750-550X
  • Serna, Naroa|||0000-0001-5682-8198
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
Raw data of a set of experiments aimed to explore the properties of the diftheria toxin translocation domain placed in receptor-targeted self-assembling nanoparticles based on recombinant proteins.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Diphtheria Toxin Translocation Domain Impairs Receptor Selectivity in Cancer Cell-Targeted Protein Nanoparticles

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Parladé, Eloi|||0000-0001-5750-550X
  • Serna, Naroa|||0000-0001-5682-8198
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
Protein-based materials intended as nanostructured drugs or drug carriers are progressively gaining interest in nanomedicine, since their structure, assembly and cellular interactivity can be tailored by recruiting functional domains. The main bottleneck in the development of deliverable protein materials is the lysosomal degradation that follows endosome maturation. This is especially disappointing in the case of receptor-targeted protein constructs, which, while being highly promising and in demand in precision medicines, enter cells via endosomal/lysosomal routes. In the search for suitable protein agents that might promote endosome escape, we have explored the translocation domain (TD) of the diphtheria toxin as a functional domain in CXCR4-targeted oligomeric nanoparticles designed for cancer therapies. The pharmacological interest of such protein materials could be largely enhanced by improving their proteolytic stability. The incorporation of TD into the building blocks enhances the amount of the material detected inside of exposed CXCR4 cells up to around 25-fold, in absence of cytotoxicity. This rise cannot be accounted for by endosomal escape, since the lysosomal degradation of the new construct decreases only moderately. On the other hand, a significant loss in the specificity of the CXCR4-dependent cellular penetration indicates the unexpected role of the toxin segment as a cell-penetrating peptide in a dose-dependent and receptor-independent fashion. These data reveal that the diphtheria toxin TD displayed on receptor-targeted oligomeric nanoparticles partially abolishes the exquisite receptor specificity of the parental material and it induces nonspecific internalization in mammalian cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recombinant vaccines in 2022, a perspective from the cell factory

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Parladé, Eloi|||0000-0001-5750-550X
  • Vázquez, Esther|||0000-0003-1052-0424
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80's, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recombinant Proteins for Assembling as Nano- and Micro-Scale Materials for Drug Delivery, A Host Comparative Overview

  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Márquez-Martínez, Merce|||0000-0003-2157-5850
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Ferreira, Luis|||0000-0002-4883-1693
  • Vázquez, Esther|||0000-0003-1052-0424
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Parladé, Eloi|||0000-0001-5750-550X
By following simple protein engineering steps, recombinant proteins with promising applications in the field of drug delivery can be assembled in the form of functional materials of increasing complexity, either as nanoparticles or nanoparticle-leaking secretory microparticles. Among the suitable strategies for protein assembly, the use of histidine-rich tags in combination with coordinating divalent cations allows the construction of both categories of material out of pure polypeptide samples. Such molecular crosslinking results in chemically homogeneous protein particles with a defined composition, a fact that offers soft regulatory routes towards clinical applications for nanostructured protein-only drugs or for protein-based drug vehicles. Successes in the fabrication and final performance of these materials are expected, irrespective of the protein source. However, this fact has not yet been fully explored and confirmed. By taking the antigenic RBD domain of the SARS-CoV-2 spike glycoprotein as a model building block, we investigated the production of nanoparticles and secretory microparticles out of the versions of recombinant RBD produced by bacteria (Escherichia coli), insect cells (Sf9), and two different mammalian cell lines (namely HEK 293F and Expi293F). Although both functional nanoparticles and secretory microparticles were effectively generated in all cases, the technological and biological idiosyncrasy of each type of cell factory impacted the biophysical properties of the products. Therefore, the selection of a protein biofabrication platform is not irrelevant but instead is a significant factor in the upstream pipeline of protein assembly into supramolecular, complex, and functional materials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins

  • Álamo, Patricia|||0000-0003-0510-5701
  • Parladé, Eloi|||0000-0001-5750-550X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Ferreira, Luís C.S.
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Among bio-inspired protein materials, secretory protein microparticles are of clinical interest as self-contained, slow protein delivery platforms that mimic secretory granules of the human endocrine system, in which the protein is both the drug and the scaffold. Upon subcutaneous injection, their progressive disintegration results in the sustained release of the building block polypeptides, which reach the bloodstream for systemic distribution and subsequent biological effects. Such entities are easily fabricated in vitro by Zn-assisted cross-molecular coordination of histidine residues. Using cationic Zn for the assembly of selected pure protein species and in the absence of any heterologous holding material, these granules are expected to be nontoxic and therefore adequate for different clinical uses. However, such presumed biosafety has not been so far confirmed and the potential protein dosage threshold not probed yet. By selecting the receptor binding domain (RBD) from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein as a model protein and using a mouse lab model, we have explored the toxicity of RBD-made secretory granules at increasing doses up to ∼100 mg/kg of animal weight. By monitoring body weight and biochemical blood markers and through the histological scrutiny of main tissues and organs, we have not observed systemic toxicity. Otherwise, the bioavailability of the material was demonstrated by the induction of specific antibody responses. The presented data confirm the intrinsic biosafety of artificial secretory granules made by recombinant proteins and prompt their further clinical development as self-contained and dynamic protein reservoirs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Protein features instruct the secretion dynamics from metal-supported synthetic amyloids

  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Hexahistidine-tagged proteins can be clustered by divalent cations into self-containing, dynamic protein depots at the microscale, which under physiological conditions leak functional protein. While such protein granules show promise in clinics as time-sustained drug delivery systems, little is known about how the nature of their components, that is, the protein and the particular cation used as cross-linker, impact on the disintegration of the material and on its secretory performance. By using four model proteins and four different cation formulations to control aggregation, we have here determined a moderate influence of the used cation and a potent impact of some protein properties on the release kinetics and on the final fraction of releasable protein. In particular, the electrostatic charge at the amino terminus and the instability and hydropathicity indexes determine the disintegration profile of the depot. These data offer clues for the fabrication of efficient and fully exploitable secretory granulesthat being biocompatible and chemically homogenous allow their tailored use as drug delivery platforms in biological systems.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Márquez, Merce
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Ferreira, Luis|||0000-0002-4883-1693
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Parladé, Eloi|||0000-0001-5750-550X
  • Villaverde, Antonio|||0000-0002-2615-4521
The development of new and more efficient vaccination approaches is a constant need, due to the pressure of historical and emerging infectious diseases and the limited efficacy and universality of the current vaccination technologies. Peptides and recombinant proteins have been explored for decades as subunit vaccines for bacterial and viral infections, presented either as soluble protein species or as virus-like assemblies. Recently, synthetic secretory protein-only microscale granules have been developed as dynamic depots for sustained protein release. They are based on the reversible coordination between ionic Zn and histidine residues, which promotes a fast formation of granular particles in vitro out of soluble protein and a slow release of such building block protein in vivo through the physiological chelation of the metal. Such an endocrine-like platform represents a new drug delivery system fully validated in oncology by which soluble and functional protein drugs are progressively released from the granules and made available for antitumor activities upon subcutaneous administration. By exploring such an approach for immunization here, microparticles made of a recombinant form of the receptor binding domain (RBD) of SARS-CoV-2 were tested as an antigen delivery system for induction of antibody responses against the virus upon administration of the material in the absence of added adjuvants. Also, the comparison between protein materials produced in bacterial, mammalian, or insect cell factories has demonstrated a moderate impact of protein glycosylation on the final immunological performance of the system. Therefore, we propose the consideration of synthetic protein secretory granules as a new sustainable immunization platform based on fully manageable, self-organized, and self-formulated immunogens, aimed at reducing the dosage, costs, and complexity of vaccination regimens.